The head of SHINE Technologies’ therapeutics division says the company is moving from research and development into the commercial stage for a precision cancer treatment product.

The Janesville company recently submitted its “drug master file” to the FDA, which includes information on facilities, procedures and other details for production of non-carrier-added lutetium-177 chloride. This radiopharmaceutical product is paired with “cancer-seeking” molecules to target and damage or destroy cancer cells, Chris Vessell explained in an interview yesterday.

“We’ve been participating in really early-stage and pre-clinical trials, and with this filing, this means our customers can use our product in number one, commercially available drugs, as well as later-stage clinical trials,” he said.

Click here to read the full article.